Kickfund

A-Metal specializes in manufacturing compact, safe, and affordable laser powder bed fusion machines for metal additive manufacturing. Their unique cartridge system enables operation without a laboratory environment, making metal 3D printing accessible to small and medium enterprises and research departments for prototyping, testing, or limited production.

CompagOs is a company dedicated to improving cancer treatment outcomes by providing personalized solutions for patients with bone cancer. The company utilizes 3D bioprinting technology to recreate the unique cancerous conditions of a patient's bone in a controlled laboratory environment, allowing oncologists to assess different drug reactions and determine the most effective treatment options. By using mineralized three-dimensional bio-printed bone organoids, CompagOs surpasses the limitations of conventional animal and 2D models, offering a more accurate representation of human physiological conditions. This technology not only aids in personalized patient care but also serves as a powerful tool for drug development, enabling researchers to evaluate drug efficacy in a realistic and patient-relevant setting.

A-Metal specializes in manufacturing compact, safe, and affordable laser powder bed fusion machines for metal additive manufacturing. Their unique cartridge system enables operation without a laboratory environment, making metal 3D printing accessible to small and medium enterprises and research departments for prototyping, testing, or limited production.

CustomSurg is a company focused on enhancing the treatment of complex bone fractures, particularly those involving joints. It develops fracture-specific bone plates that are tailored to match the unique anatomy of individual patients using advanced technologies such as computer tomography and 3D printing. This personalized approach provides improved stability for bone repairs, which can significantly reduce surgery time and lower long-term healthcare costs for patients. By offering a software solution for optimized surgical planning and designing patient-specific implants and instruments, CustomSurg shifts the treatment strategy from a subjective to an objective framework, aiming to improve outcomes for approximately 400,000 trauma patients in a market valued at $1.2 billion. The involvement of a Harvard Medical School surgeon in directing the medical aspects of the company adds a layer of credibility to its innovative offerings.